Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | HAO1 | Q9UJM8 | 4/20 | 0.41 |
| ▸ | PLAU | P00749 | 7/20 | 0.40 |
| ▸ | PLG | P00747 | 5/20 | 0.40 |
| ▸ | PLAT | P00750 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851547 | 0.88 | KDM4E (0.47) | F10PLAUPLGPLATSCN9A | |
| SCHEMBL921728 | 0.77 | SCN9A (0.49) | SCN9A | |
| SCHEMBL851729 | 0.76 | F10 (0.46) | F10HAO1SCN9ANTRK1DHODH | |
| SCHEMBL850679 | 0.76 | F10 (0.46) | F10HAO1SCN9ANTRK1DHODH | |
| SCHEMBL24684391 | 0.70 | PTGER4 (0.43) | F10PPARGP2RY1DHODHCYP1A2 | |
| SCHEMBL8773194 | 0.70 | CHRM5 (0.42) | F10SCN9A | |
| SCHEMBL7372993 | 0.69 | TDP1 (0.52) | P2RY1DHODHCYP1A2CYP2C19 | |
| SCHEMBL6580937 | 0.69 | F2 (0.56) | F10HAO1PLAUPLGPLAT | |
| SCHEMBL9138429 | 0.68 | FAAH (0.61) | PPARGCYP2C9 | |
| SCHEMBL923011 | 0.68 | EPAS1 (0.47) | F10SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2014-07-17 | — | — | US | disclosed |
| US-8722930-B2 | Protease inhibitors | ORION CORPORATION (FI) | 2014-05-13 | — | — | US | disclosed |
| US-20120136002-A1 | PROTEASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-31 | — | — | US | disclosed |
| EP-2432556-A1 | PROTEASE INHIBITORS | Orion Corporation (FI) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | F10 152/4885HAO1 2312/4885PLAU 141/4885 |
| US-20120136002-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | F10 152/4885HAO1 2312/4885PLAU 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.